Workflow
Globenewswire
icon
Search documents
Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions
Globenewswire· 2026-02-24 13:00
First-of-its-kind partnership designed to educate and mobilize patients to imagine a healthier tomorrowDAYTONA BEACH, Fla. and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- The Ladies Professional Golf Association (LPGA) and Ardelyx (Nasdaq: ARDX), a biopharmaceutical company with a vision of creating a healthier tomorrow for patients, today announced a multi-year partnership naming Ardelyx as an official corporate pharmaceutical Marketing Partner of the LPGA Tour. The exclusive partnership unites two o ...
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
Globenewswire· 2026-02-24 13:00
PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 11:10 a.m. ET in Boston, MA. A live webcast of the presentation will be available on the News ...
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results
Globenewswire· 2026-02-24 13:00
SOMERSET, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 10, 2026, to review fourth-quarter and full-year 2025 financial results. During the conference call and accompanying webcast, senior management will provide an overview of quarterly and full-year financial performance. Investors and other interested parties may access the live audio webcast via ...
Septerna to Present at TD Cowen 46th Annual Health Care Conference
Globenewswire· 2026-02-24 13:00
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 3:10 p.m. ET in Boston. A live webcast of the presentation will be available in the investors section of the compan ...
zSpace Partners with Eight Million Stories to Reignite Hope and Break Barriers for At Promise Youth
Globenewswire· 2026-02-24 13:00
Immersive Career Exploration and Skill-Building Technology Helps Formerly Incarcerated and Disconnected Students Unlock Their PotentialSAN JOSE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- zSpace, Inc. (NASDAQ: ZSPC), a leading provider of augmented and virtual reality (AR/VR) solutions for education, today announced a partnership with Eight Million Stories, Inc., a nonprofit organization founded to disrupt the school-to-prison pipeline. Through immersive, hands-on learning, zSpace technology is helping forme ...
CPI Aerostructures Receives Additional Orders Worth $9M From Lockheed Martin for F-16 Structural Assemblies
Globenewswire· 2026-02-24 13:00
EDGEWOOD, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CPI Aerostructures, Inc. (“CPI Aero” or the “Company”) (NYSE American: CVU) announced that Lockheed Martin Aeronautics has placed several additional orders totaling $9 million against a previously announced Long Term Agreement to manufacture the Rudder Island Drag Chute Canister (RI/DCC) assemblies for the F-16 Block 70/72 fighter jets. These new orders will see deliveries continue through 2028. CPI Aero delivered its first RI/DCC assembly for the F-16 Block ...
IN8bio to Present at TD Cowen 46th Annual Health Care Conference
Globenewswire· 2026-02-24 13:00
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, at 9:50 am ET. William Ho will be giving a company presentation highlighting IN8bio’s latest achievements and upcoming milestones. The conference, to be held Mar ...
Axe Compute Explores Strategic Options for its Helomics Business as Company Sharpens AI Compute Focus
Globenewswire· 2026-02-24 13:00
PITTSBURGH, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axe Compute, Inc. (NASDAQ: AGPU) today announced that it has engaged Cardiff Advisory LLC, a leading investment bank specializing in life sciences and strategic advisory services, to assist the Company in exploring strategic alternatives for its Helomics Business. The strategic review process will be conducted under the oversight of the Company’s Board of Directors and may include a sale, partnership, licensing arrangement, joint venture, or other transaction in ...
Moomoo and W!se Award $10,000 to Queens Gateway to Health Sciences Secondary School as Part of Student Stock Showdown Challenge
Globenewswire· 2026-02-24 13:00
JERSEY CITY, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Moomoo, a leading global investment and trading platform, today named Queens Gateway to Health Sciences Secondary School the winning school in the Student Stock Showdown challenge, a 13-week paper trading competition delivered in partnership with Working in Support of Education (W!se), an educational nonprofit based in New York City. The recognition honors Queens Gateway’s strong overall performance and student engagement throughout the program, which bro ...
ORYZON Receives European Medicines Agency Approval to Initiate a Phase II Study of iadademstat in Essential Thrombocythemia
Globenewswire· 2026-02-24 13:00
MADRID and CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that the European Medicines Agency (EMA) has authorized its Clinical Trial Application (CTA) to initiate a Phase II study of iadademstat, Oryzon’s potent and selective LSD1 inhibitor currently in clinical development in oncology and hematology, for the treatment of essential thrombocythemia ...